News related to Celontin (Methsuximide) and/or conditions it is approved for
Researchers Find Relationship Between Brain Fluid And Adult Seizures
Source: Tropical Diseases News From Medical News Today [2008.11.06]
According to a new study published early online and in the December issue of Lancet Neurology, researchers better understand the disease mechanisms behind brain seizures that are due to the tapeworm-derived parasitic infection called neurocysticercosis. Their finding that the seizures are frequently associated with fluid or perlesional oedema (PO) around dead calcified cysticercal granulomas (immune cells) may lead to better possible treatment targets.
Common Sedative Linked To Deaths In Patients With Prolonged Seizures
Source: Epilepsy News From Medical News Today [2008.10.29]
Patients treated for their prolonged seizures with the sedative propofol may be at high risk for complications and even death. New research presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that the use of propofol as an antiepileptic agent in patients with refractory status epilepticus (RSE), prolonged seizures that do not respond to initial treatment, was associated with significant mortality and morbidity.
UCB's Vimpat® Approved By U.S. FDA As Adjunctive Therapy For Partial Onset Seizures In Adults
Source: Epilepsy News From Medical News Today [2008.10.29]
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Vimpat® (lacosamide), a new antiepileptic drug (AED). Vimpat® is for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. "Having a new antiepileptic drug option may offer adults with partial onset seizures the chance to obtain seizure control.
Sedative Could Be Deadly in People With Seizures
Source: MedicineNet Seizure Specialty [2008.10.29]
Title: Sedative Could Be Deadly in People With Seizures
Category: Health News
Created: 10/29/2008 2:00:00 AM
Last Editorial Review: 10/29/2008
Brain Cancer Symptoms: Headaches and Seizures
Source: MedicineNet Brain Tumor Specialty [2008.10.23]
Title: Brain Cancer Symptoms: Headaches and Seizures
Category: Doctor's Views
Created: 10/23/2008
Last Editorial Review: 10/23/2008
VIMPAT (lacosamide), A New Epilepsy Treatment For Adults With Partial Onset Seizures, Launched In The UK
Source: Epilepsy News From Medical News Today [2008.10.14]
Vimpat (lacosamide), a new adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older, has been launched in the UK. The efficacy of VIMPAT® as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicentre, randomised, placebo-controlled clinical trials with a 12-week maintenance period.
Keppra XR Approved for Partial-Onset Seizures
Source: MedicineNet Seizure Specialty [2008.09.16]
Title: Keppra XR Approved for Partial-Onset Seizures
Category: Health News
Created: 9/16/2008 2:00:00 AM
Last Editorial Review: 9/16/2008
Keppra XR(TM) Approved In The U.S. As Add-On To Other Antiepileptic Treatments For People With Partial Onset Seizures
Source: Epilepsy News From Medical News Today [2008.09.15]
UCB announced that the U.S. Food and Drug Administration (FDA) has approved Keppra XR(TM) (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial onset seizures who are 16 years of age and older. Keppra XR(TM) is expected to be available in U.S. pharmacies at the end of September 2008. The goal of therapy with antiepileptic drugs (AEDs) is freedom from seizures and minimal side effects.
Vimpat(R) Approved In Europe - First New Epilepsy Treatment For Partial-Onset Seizures In Three Years
Source: Epilepsy News From Medical News Today [2008.09.03]
UCB announced that the European Commission (EC) has approved Vimpat® (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat® is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
FDA Approves First Generic Divalproex Sodium To Treat Seizures, Migraine Headaches And Bipolar Disorder
Source: Headache / Migraine News From Medical News Today [2008.08.01]
The U.S. Food and Drug Administration approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches. "Generic drugs undergo a rigorous scientific review to ensure that they will provide the patient with the same amount of high quality, safe and effective drug as the name brand product," said Gary J.
Febrile Seizures
Source: MedicineNet Pediatric Epilepsy Surgery Specialty [2008.05.09]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008
Last Editorial Review: 5/9/2008
Seizures Symptoms and Types
Source: MedicineNet Gaucher Disease Specialty [2007.12.13]
Title: Seizures Symptoms and Types
Category: Diseases and Conditions
Created: 1/31/2005 8:07:00 AM
Last Editorial Review: 12/13/2007
Falls In Blood Oxygen Levels May Be Key To Sudden Death In Some Epilepsy Patients
Source: Epilepsy News From Medical News Today [2008.11.18]
A new study by researchers at UC Davis Medical Center suggests that the sudden unexplained deaths of some epilepsy patients may be a result of their brains not telling their bodies to breathe during seizures. "Significant drops in blood oxygen levels are more common than we thought in patients with partial seizures," said study senior author Masud Seyal, a professor of neurology at UC Davis Medical Center and director of the UC Davis Comprehensive Epilepsy Program.
Lutheran General Hospital Neurologist Treats Epilepsy With Vagal Nerve Stimulation (VNS) Therapy
Source: Epilepsy News From Medical News Today [2008.11.07]
Daniel Brewer of Palatine has gone from having four to five epileptic seizures a day to a few minor ones in the six months since his surgery for vagal nerve stimulation (VNS) therapy to help control electric signals from his brain. "This has completely changed my life," said the 29-year-old who has had 'every drug known to man' to treat his epilepsy, which he has struggled to control for the past 16 years.
Epilepsy Foundation Seeking Signatures
Source: Epilepsy News From Medical News Today [2008.10.27]
In 2009 in the USA, a new President, 535 members of Congress and nearly 10,000 state legislators will take office. By signing our petition, you can help us persuade them to support policies that improve the lives of the three million American families affected by epilepsy. More than 3 million Americans have epilepsy (seizures) and 200,000 new cases are diagnosed yearly. For most, there is no cure and many with epilepsy face discrimination and difficulty accessing care.
Epilepsy Phenome/Genome Project - First And Largest Research Study Of Its Kind To Understand What Causes Epilepsy
Source: Epilepsy News From Medical News Today [2008.10.27]
The Epilepsy Phenome/Genome Project (EPGP) consists of a group of researchers, physicians, coordinators, family members, people with epilepsy, advocates, and friends working together unlock the mysteries of epilepsy. EPGP is the first and largest research study of its kind to understand what causes epilepsy, why people respond differently to medications, and why some families have several people with seizures.
Dangerous Side-Effects Of Epilepsy Drugs Reduced In New Research
Source: Epilepsy News From Medical News Today [2008.09.08]
A breakthrough method has been found to reduce the dangerous side-effects of a medicine that successfully tackles epilepsy, according to research released at the British Pharmaceutical Conference (BPC) in Manchester. Epilepsy is an incurable condition which causes people to suffer repeated seizures caused by a burst of abnormal electrical activity in the brain. It affects about one in 30 people in the UK.
3T MRI Leads To Better Diagnosis For Focal Epilepsy
Source: Epilepsy News From Medical News Today [2008.09.06]
3T MRI is better at detecting and characterizing structural brain abnormalities in patients with focal epilepsy than 1.5T MRI, leading to a better diagnosis and safer treatment of patients, according to a recent study conducted at the Oregon Health and Science University in Portland, OR. "Patients with focal epilepsy have recurrent seizures that result from a specific area of their brain, usually due to a structural brain abnormality," said Bronwyn E.
|
